375 5. Complicanze precoci [18] Lucchini G, Willasch AM, Daniel J, et al. Epidemiology, risk factors, and prognosis of capillary leak syndrome in pediatric recipients of stem cell transplants: a retrospective single-center cohort study. Pediatr Transplant. 2016;20:1132–6. [19] Xie Z, Ghosh CC, Patel R, et al. Vascular endothelial hyperpermeability induces the clinical symptoms of Clarkson disease (the systemic capillary leak syndrome). Blood. 2012;119:4321–32. [20] Lin YT, W CY, Chang TY, Chiu CC, Wen YC, Jaing TH. The effect of tetrastarch solution for capillary leak syndrome following allogeneic hematopoietic stem cell transplantation: A report of 2 cases. Hematol Rep. 2021;5(13):8750 [21] Yabe H, Yabe M, Koike T, et al. Rapid improvement of life-threatening capillary leak syndrome after stem cell transplantation by bevacizumab. Blood. 2010;115:2723–4. [22] Siddall E, Khatri M, Radhakrishnan. Capillary leak syndrome: etiologies, pathophysiology, and management. Kidney International 2017;92(1):37-46 [23] Khosla J, Yeh AC, Spitzer TR, Dey BR. Hematopoietic stem cell transplant-associated thrombotic microangiopathy: current paradigm and novel therapies. Bone Marrow Transplant. 2018;53:129–37. [24] Scully M, Cataland S, Coppo P, International Working Group for Thrombotic Thrombocytopenic Purpura, et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017;15:312–22 [25] Young JA, Pallas CR, Knovich MA. Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis. Bone Marrow Transplant 2021;56:1805-1817 [26] Meri S, Bunjes D, Cofiell R, Jodele S. The role of Complement in HSCT-TMA: Basic Science to Clinical Practice. Adv Ther 2022;39()):3896-3915 [27] Jodele S, Zhang K, Zou F, et al. The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy. Blood. 2016;127:989–96. [28] Khosla J, Yeh AC, Spitzer TR, Dey BR. Hematopoietic stem cell transplant-associated thrombotic microangiopathy: current paradigm and novel therapies. Bone Marrow Transplant. 2018;53:129–37. [29] Dvorak CC. TA-TMA: state of the art for diagnosis and treatment. Blood Adv 2020;4(1):217 [30] Jodele S, Dandoy CE, Sabulski A, Koo J, Lane A, Myers KC, et al. Transplantation-Associated Thrombotic Microangiopathy Risk Stratification: Is There a Window of Opportunity to Improve Outcomes? Transplant Cell Ther 2022;28(7):392.e1-392.e9. [31] Uderzo C, Jodele S. Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Consensus Based Diagnostic and Therapeutic Recommendations: Which TA-TMA Patients to Treat and When? J Bone Marrow Res 2014;2:3 [32] Zhang R, Zhou M, Qi J, Miao W, Zhang Z, Wu D, et al. Efficacy Safety of Eculizumab in the Treatment of Transplant-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis. Front Immunol 2021;https://doi.org/10.3389/ fimmu.2020.564647 [33] Wu J, Fu HX, He Y, Mo XD, Liu X, Cai X, et al. Risk factors and Outcomes of diffuse alveolar hemorrhage after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 2021;56:2097-2107 [34] Majhail NS, Parks K, Defor TE, Weisdorf DJ. Diffuse alveolar hemorrhage and infection-associated alveolar hemorrhage following hematopoietic stem cell transplantation: related and high-risk clinical syndromes. Biol Blood Marrow Transplant. 2006;12:1038–46 [35] Rathi NK, Tanner AR, Dinh A, et al. Low-, medium and high-dose steroids with or without aminocaproic acid in adult hematopoietic SCT patients with diffuse alveolar hemorrhage. Bone Marrow Transplant. 2015;50:420–6. [36] Afessa B, Tefferi A, Litzow MR, Peters SG. Outcome of diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients. Am J Respir Crit Care Med. 2002;166:1364–8. [37] Chen Q, Zhao X, Fu HX, Chen YH, Zhang YY, Wang JZ, et al. Posterior reversible encephalopathy syndrome (PRES) after haploidentical hematopoietic stem cell transplantation: incidence, risk factors and outcomes. Bone Marrow Transplant 2020;55:2035-2042 [38] Schmidt V, Prell T, Treschl A, Klink A, Hochhaus A, Sayer HG. Clinical Management of Posterior Reversible Encephalopathy Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation: A Case series and Review of the Literature. Acta Haematol. 2016;135(1):1-10 [39] Hinduja A. Posterior Reversible Encephalopathy Syndrome: Clinical Features and Outcome. Front Neurol 2020;.https://doi. org/10.3389/fneur.2020.00071 [40] Torelli GF, Natalino F, Barberi W, Iori AP, Andreoli C, Valle V, et al. Early onset of posterior reversible encephalopathy syndrome (PRES) during Cyclosporine-A infusion. Leuk Res 2011;35(10):14231424 [41] Anderson RC, Patel V, Sheikh-Bahaei N, Liu CSJ, Rajamohan AG, Shiroishi MS, et al. Posterior Reversible Encephalopathy Syndrome (PRES): Pathophysiology and Neuro-Imaging Front Neurol 2020;11:463 [42] Hun M, Tian J, Xie M, She Z, Abdriahman S, Han P, et al. Analysis of risk factors Associated with Poor Outcome in Posterior Reversible Encephalopathy Syndrome After treatment in Children: Systematic Review and Meta-Analysis. Front Neurol 2020;11:938 [43] McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology. 1984;4:116–22 [44] Corbacioglu S, Jabbour EJ, Mohty M. Risk factors for development of and progression of hepatic veno-occlusive disease/ sinusoidal obstruction syndrome. Biol Blood Marrow Transplant. 2019;25:1271–80. [45] Cairo MS, Cooke KR, Lazarus HM, Chao N. Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS/VOD after haematopoietic cell transplantation. Br J Haematol. 2020;190:822–36 [46] Chan SS, Colecchia A, Duarte RF, Bonifazi F, Ravaioli F, Bouris JH. Imaging in Hepatic Veno-occlusive Disease/Sinusoidal Obstruction Syndrome. Biol Blood Marrow Transplant. 2020;26(10):1770-1779 [47] Richardson PG, Riches ML, Kernan NA, Brochstein JA, Mineishi S, Termuhlen AM, et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood 2016;127:1656-1665
RkJQdWJsaXNoZXIy ODUzNzk5